External Content

The following content is sourced from external partners. We cannot guarantee that it is suitable for the visually or hearing impaired.

(Bloomberg) -- House Democrats have started what they called an “in-depth” investigation into the pricing of drugs for neurological condition multiple sclerosis, the latest attempt by U.S. politicians to pressure manufacturers to lower costs.

Seven drugmakers -- Biogen Inc., Sanofi, Novartis AG, Roche Holding AG, Bayer AG, Merck KGaA’s EMD Serono unit and Teva Phamaceuticals Industries Ltd. -- received letters requesting information on pricing strategies from Elijah Cummings and Peter Welch, two representatives who sit on the House Committee on Oversight and Government Reform.

Some pharmaceutical companies appear to be “setting new, higher prices in lockstep with competitors -- a strategy known as ‘shadow pricing,’” Cummings and Welch said, noting that the average annual cost of therapy had increased to more than $60,000 in 2015 from about $16,000 in 2004.

Shares of Biogen, the only U.S.-based company in the group, was down 2.7 percent to $286 at 12:41 p.m., amid declines in the stock markets Thursday.

Representatives for the seven drugmakers didn’t immediately respond to requests for comment. The letter was made public after business hours in Europe and Israel, where the six other companies are headquartered.

Merck KGaA, based in Darmstadt, Germany, is unrelated to Merck & Co., the U.S. drugmaker.

--With assistance from Justin Mattingly

To contact the reporter on this story: Caroline Chen in San Francisco at cchen509@bloomberg.net.

To contact the editors responsible for this story: Drew Armstrong at darmstrong17@bloomberg.net, Cecile Daurat

©2017 Bloomberg L.P.

Neuer Inhalt

Horizontal Line


swissinfo EN

The following content is sourced from external partners. We cannot guarantee that it is suitable for the visually or hearing impaired.

Join us on Facebook!

subscription form

Form for signing up for free newsletter.

Sign up for our free newsletters and get the top stories delivered to your inbox.







Click here to see more newsletters

Bloomberg